Acumen Pharmaceuticals Inc expected to post a loss of 26 cents a share - Earnings Preview

Acumen Pharmaceuticals

10/05/2024 15:55

* Acumen Pharmaceuticals Inc  ABOS.OQ   ABOS.O  is expected
to show no change in quarterly revenue when it reports 
results on May 14 for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Acumen Pharmaceuticals
Inc is
for a loss of 26 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Acumen
Pharmaceuticals Inc is $14.00​, above​ its last closing price
of $3.57. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.30       -0.26      -0.28     Missed  9.8
 Jan. 1 0001   -0.27       -0.27      -0.24     Beat    9.8
 Jun. 30 2023  -0.34       -0.35      -0.28     Beat    19.1​
 Mar. 31 2023              -0.35      -0.28     Beat    19.1
 ​​Jan.                    -0.26      -0.32     Missed  -25.3
 1 0001                                                 
 Jan. 1 0001   -0.19       -0.23      -0.26     Missed  -13.1​
 Jun. 30 2022  -0.24       -0.24      -0.25     Missed  -2
 Jan. 1 0001   -0.17       -0.17      -0.23     Missed  -38.6
 This summary was machine generated May 10 at 14:55 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)